Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Fertility May Be Preserved With Triptorelin Adjuvant to Chemotherapy in Younger Breast Cancer Patients

September 5th 2014

Long-term follow-up of a phase III clinical trial shows strong trends toward a greater likelihood of resuming menses and becoming pregnant when a luteinizing hormone-releasing hormone (LH-RH) analog is administered with chemotherapy in patients with breast cancer

In Early Breast Cancer, Outcomes Affected by Tumor Biology and Choice of Local Treatment

September 5th 2014

Breast conserving therapy (BCT) improves overall survival compared with other local treatments in patients with stage I breast cancer, according to an examination of the National Cancer Database (NCDB).

Dr. Sisco Discusses Complications After Bilateral and Unilateral Mastectomies with Immediate Reconstruction

September 5th 2014

Mark Sisco, MD, Clinical Assistant Professor, Division of Plastic and Reconstructive Surgery, NorthShore Univeristy HealthSystem, discusses the results of a NSQIP analysis of 30-day complications after bilateral versus unilateral mastectomy with immediate reconstruction

Dr. Verma Discusses Clinical Trial Endpoints in Metastatic Breast Cancer

September 5th 2014

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in early-stage breast cancer.

Targeting the Androgen Receptor: New Hope for Aggressive Forms of Prostate and Breast Cancer

September 5th 2014

Although hormone-targeting strategies have been a mainstay of prostate and breast cancer therapies for decades, an improved understanding of the mechanisms underlying these malignancies has led researchers to focus fresh attention on the complex activity of the androgen receptor (AR) as a point of attack.

ASCO Issues New Guideline for Advanced HER2-Negative Breast Cancer

September 3rd 2014

The American Society of Clinical Oncology (ASCO) has released a new clinical practice guideline on the treatment of patients with advanced HER2-negative breast cancer.

Dr. Tripathy Provides an Overview of the SystHERs Registry

September 2nd 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, provides an overview of the SystHERs registry.

"Angelina Jolie Effect" Sparks More BRCA Testing at Cancer Center

September 2nd 2014

The actress Angelina Jolie's decision to undergo a preventive double mastectomy after learning she carried the BRCA1 gene mutation-associated with an increased risk of breast and/or ovarian cancer-apparently sparked an "Angelina effect" on public health.

Subtype, pCR Predict Locoregional Recurrence Following Neoadjuvant Therapy

September 2nd 2014

The combination of multiple independent factors minimized the impact of baseline stage for predicting locoregional recurrence (LRR) following neoadjuvant chemotherapy in patients with breast cancer, according to a large retrospective analysis presented in advance of the 2014 Breast Cancer Symposium.

Patient Decisions About Bilateral Mastectomy Influenced by Anxiety, Worry About Recurrence

September 2nd 2014

One of the first studies to prospectively examine women's breast surgery preferences has revealed that newly diagnosed women with breast cancer who decide to undergo contralateral prophylactic mastectomy (CPM), may be making this decision as result of high anxiety and fear of recurrence, rather than relying on evidence-based information.

Some Surgical Complications Greater With Bilateral Versus Unilateral Mastectomy

September 2nd 2014

Postsurgery complications are infrequent among breast cancer patients undergoing surgery with reconstruction; however, according to a large database study, the rates of certain complications, including reoperation, blood transfusion, and implant loss, are higher with bilateral mastectomy versus unilateral mastectomy.

Signed Letters From Family Physicians May Increase Mammography Screening Rates

September 2nd 2014

Women who received signed letters from their family physician along with scheduled postcard reminders are more likely to return for mammography screening than women who only received a postcard

Dr. Isaacs on the Importance of Genetic Counseling

September 2nd 2014

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the importance of genetic counseling and the role of the genetic counselor

Dr. Arkenau Discusses AZD4547 and FGFR Amplification in Advanced Solid Tumors

August 28th 2014

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of AZD4547 in patients with advanced tumors.

Novel Breast Cancer Agents Aimed at Overcoming Endocrine Therapy Resistance

August 28th 2014

Although advances in endocrine therapy for women with estrogen receptor (ER)-positive breast cancer have been made in recent years, de novo and acquired resistance to treatments remain important clinical problems, and efforts to identify effective modalities to overcome this challenge continue.

O'Shaughnessy Provides Fresh Insights Into Specificity in TNBC Therapy

August 25th 2014

Although no cytotoxic agents are currently correlated with specific subtypes of triple negative breast cancer (TNBC), recent findings indicate that targeting genomic stability, antimetastatic mechanisms, and protein expression characteristics are promising approaches for future TNBC treatments.

Dr. Pagani Discusses Aromatase Inhibitors for Premenopausal Women with Breast Cancer

August 22nd 2014

Olivia Pagani, MD, Institute of Oncology, Southern Switzerland, discusses the result of a joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptorâ€“positive (HR+) breast cancer who were treated with the aromatase inhibitor exemestane.

Dr. Brufsky on Adjuvant Bisphosphonates for Patients with Breast Cancer

August 21st 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.

DHEA Therapy Offers Relief From Vaginal Symptoms in Cancer Survivors

August 21st 2014

A randomized multicenter trial examining the efficacy of adding dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women.

Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer

August 18th 2014

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.